Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

Interim CEO Brent Shafer said the medical products maker is ready to begin a new era after several years of “heavy lifting” ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Ariel Fund declined -0.66% in the quarter, falling shy of Russell 2500 Value and Russell 2500 Indices, which returned -0.26% ...

They invest in public stocks and bonds, and their clients are increasingly sensitive to costs. Their most popular products these days are passive index trackers with razor-thin fees, often just a few ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Former NBA player Michael Carter-Williams is hoping to get a WNBA franchise in Boston whether it's through expansion or being ...

Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.